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ABSTRACT
Introduction Eating disorders (EDs) are complex 
pathologies which require equally complex treatment 
strategies. These strategies should be multidisciplinary, 
personalised interventions, performed in appropriate 
settings along a healthcare continuum from inpatient 
to community care. Personalisation, and the complexity 
of levels of care and interventions make evaluation of 
treatments difficult. The present study aims to measure 
the effectiveness of a complex treatment programme 
for EDs which includes hospitalisation, day hospital and 
outpatient settings. Our purpose is to assess the complete 
therapeutic process of each patient through all these levels 
of care, capturing the multiplicity of trajectories that a 
programme of these characteristics involves.
Methods and analysis This protocol describes a 
multicentre, naturalistic, observational study. All patients 
starting between November 2017 and October 2020 in a 
healthcare network for EDs in Spain are being invited to 
participate. The first phase of intensive change monitoring 
to November 2020 is followed by lower intensity follow- 
up until October 2025. In the first phase progress of all 
participants is assessed every 3 weeks using specific 
measures for ED and the Clinical Outcomes Routine 
Evaluation system, a family of instruments specifically 
designed to measure change in psychotherapy. In the 
second phase data collection will happen quarterly. 
Both cross- sectional and longitudinal analyses will be 
conducted, with a special focus on patterns and predictors 
of change studied through multilevel linear models.
Ethics and dissemination The study has been approved 
by the Research Bioethics Committee of the University of 
Barcelona (no. IRB00003099) and the ethical committee 
of ITA Mental Health, the organisation to which all 
participating centres belong. Dissemination will be 
in papers for peer- reviewed research journals and to 
clinicians working with ED.
Trial registration number NCT04127214.
INTRODUCTION
Eating disorders (EDs) are multidetermined 
pathologies with serious health implications. 
With typical onset in adolescence, they can 
present throughout life1 and affect approxi-
mately nine women for every man.2 Indeed, 
prevalence reaches 12% among women aged 
12–20 years.3
Anorexia nervosa (AN) and bulimia 
nervosa (BN) are perhaps the best- known 
EDs. However, the Diagnostic and Statistical 
Manual of Mental Disorders 5th Edition4 also 
includes binge ED (BED), avoidant restrictive 
food intake disorder (ARFID), rumination 
disorders and other specified eating disor-
ders (OSFEED).
Despite these fixed categories, two- thirds 
of cases experience diagnostic migration, 
with transition from AN to BN being the 
most frequent.5 Another characteristic of 
EDs is the presence of comorbidities, most 
frequently personality, affective, anxiety and 
substance use disorders.6
In addition, the typical course of EDs is 
characterised by high rates of treatment 
drop- out (between 20% and 50%),7 together 
with frequent relapses that may reach 51% of 
cases 5 years after hospital discharge.8 Unfor-
tunately, the mortality rate for AN is as high as 
5%,8 and 3.9% for bulimia.9
Strengths and limitations of this study
 ► The present study is aimed to capture the diversity 
of patient’s trajectories through their treatment.
 ► Change is measured in the context of routine clinical 
practice, representing the heterogeneity of eating 
disorders (EDs).
 ► The long- term longitudinal measurements allow 
identification of different trajectories of change 
among ED patients under treatment.
 ► The practice- based evidence approach contributes 
to the originality of this study, whose results will be 
based on real- world data.
 ► Heterogeneity among participants may limit gener-
alisability of the findings and the lack of a control 
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The complex nature of EDs poses a challenge for the 
design of adequate treatment programmes. In this sense, 
the main clinical practice guidelines recommend treat-
ment personalization, care continuity and the administra-
tion of interventions aimed not only to recover weight, but 
also to improve the associated psychological and social 
factors.10 11 In practice, this has resulted in the design 
of different multicomponent treatments that combine 
individual, group and family interventions carried out by 
specialised interdisciplinary teams offering psychothera-
peutic, pharmacological and nutritional support.12 13
At the same time, the inherent complexity of treating 
EDs has affected evaluation of outcomes. Numerous 
investigations in this field have studied the effects of 
specific psychological, pharmacological and nutritional 
interventions,14 15 while other studies have focused on the 
assessment of treatment in different settings.12 16–20 These 
have all produced clinical improvements, with effect sizes 
on ED symptoms ranging from medium to large.
However, some studies on the evaluation of results tend 
to limit their focus to a single disorder of the EDs spec-
trum (AN, BN, BED, ARFID or others),21 22 which compli-
cates the application of findings where there is diagnostic 
migration and comorbidity.
To date, very few studies have attempted to evaluate the 
complete therapeutic process, integrating the different 
types of care (eg, hospitalisation, day hospital, outpatient 
services). Equally, few studies have tracked use of medica-
tion. The evidence generated through such naturalistic 
settings is scarce, but some high- quality international 
studies have shown rates of positive outcome ranging 
between 30% and 40% at 1- year follow- up.23 24
A possible explanation for the absence of more research 
projects of this kind may lie in the fact that such evalu-
ations are beyond the scope of randomised controlled 
trials (RCTs) which are the foundation of evidence- based 
practice (EBP). Although RCTs offer a gold- standard of 
research that has the highest internal validity for causal 
attributions, it is precisely this focus on internal exper-
imental control that precludes flexibility in research 
design to reflect both the heterogeneity of EDs and the 
typical complexity of treatments. As an alternative to 
RCTs, several authors have proposed studies of large 
samples derived from routine clinical data.25 This can 
produce generalisable data to allow comparison between 
different services and can ensure inclusion and exclusion 
criteria that are sufficiently broad to give representative 
results. Such research generates so- called practice- based 
evidence (PBE) that focuses on broad- spectrum outcome 
measures applied in daily clinical practice to complement 
EBP.26 27 These measures can be used to analyse large 
data sets from very diverse patients with the aim of having 
comparable results to generate evidence on different 
treatments and/ or services in naturalistic settings.28
Following the PBE approach, this research programme 
aims to evaluate the effectiveness of an integrated treat-
ment for EDs, specifically the ITA Model of Integrated 
Treatment of EDs (ITAMITED). This model prioritises 
care continuity through integrated hospitalisation, 
day hospital and outpatient services and in which each 
patient has personalised treatment plan. The treatment 
leans primarily on psychotherapy, which is conducted 
combining individual, group and family formats. 
Although not required for all patients, medication is 
included, targeting ED symptoms, comorbid problems 
or both. Given the multifactorial nature of EDs and the 
diversity of maintenance factors, the objectives of the 
interventions in the ITA model are not limited to weight 
improvement or other symptomatic expressions of the 
disorder, and instead extend to improve the discomfort 
created by the pathology and to promote sustainable 
personal aims and life style. As such, discharge criteria are 
not solely about remission of ED symptoms but include 
resolution of problems in mood, impulse control, anxiety, 
family relationship, affective, social and professional 
domains.
Study objectives
The main objective of this study is to assess the effective-
ness of ITAMITED as it is applied routinely in its natural 
context. We aim to measure the effects of the ITA model 
on psychological distress, and eating attitudes and symp-
toms. Benchmark comparisons will be performed to 
estimate the relative effectiveness where suitable referen-
tial data exist in the literature. The following secondary 
objectives will also be pursued:
 ► Evaluation of the contribution of each of the interven-
tion levels (ie, inpatient, day hospital and outpatient).
 ► Describe the characteristics of the study population 
from sociodemographic and clinical perspectives.
 ► Identify specific change patterns for patients with 
different diagnoses or individual characteristics.
 ► Study the psychometric properties of each instrument 
used in the study, the possible convergence between 
them and their predictive capacity regarding different 
clinical outcome indicators.
 ► Describe the main challenges in implementing a 
routine for measuring changes in clinical practice in a 
complex healthcare network.
Our main hypothesis is that the vast majority of partic-
ipants will show improvements in psychological distress 
from baseline to treatment termination. Secondary 
hypotheses include improvements in secondary outcomes, 
and are based on the sociodemographic and clinical vari-
ables measured (see the Data analysis section). Emerging 




This multicentre, prospective, observational naturalistic 
study will evaluate the effectiveness of the treatment 
for ED offered by ITA among new clients. All patients 
with a diagnosed ED admitted for treatment between 
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the ITA treatment centres will be invited to participate. 
Once a participant is enrolled, they will be followed 
throughout the therapeutic process, within any setting in 
the ITAMITED treatment network, and beyond discharge 
through booster session contacts until October 2025 or 
loss of contact.
The present study is being carried out in eight EDs 
treatment centres of the ITA network as follows:
 ► Four hospitals in Barcelona, Argentona (near Barce-
lona), Alcalá de Henares (near Madrid) and Seville.
 ► Four day hospitals and outpatient care in Barcelona, 
Sabadell (near Barcelona), Tarragona and Madrid.
Treatment
ITA and its settings
ITA ( www. itasaludmental. com) is a network of healthcare 
resources for the treatment for different mental disor-
ders in Spain. Opened in 1998 with a strong emphasis 
on psychotherapy for EDs it has grown into an exten-
sive network of services offering an integrated health-
care network that guarantees healthcare continuity. This 
continuity of care allows the patient to receive treatment 
according to the severity of their problems and their 
need for external control with high levels of coordination 
when care transfers between inpatient, day hospital and 
outpatient settings.
Inpatient hospitalisation is used to care for patients with 
more serious problems or with organic complications. 
Day hospitalisation offers treatment during the day, with 
patients spending the night at home, and allows patients 
to combine intensive therapy with studies, work or leisure 
activities. Finally, outpatient services have a dual purpose 
within ITAMITED: they are used to follow- up patients 
after hospital treatments but they are also the resource 
of choice for patients with mild symptoms who do not 
require day or inpatient hospitalisation.
Treatment features
Therapeutic principles
In each setting, patients are treated by a multidisciplinary 
team comprising a psychologist who coordinates the 
treatment, a psychiatrist, a general practitioner, a nutri-
tionist, a social worker and a team of nurses and moni-
tors. Each team shares a common view of the disorder 
and its therapy, adopting the ITA model.
ITAMITED adopts an integrative approach of psycho-
therapy.29 Cognitive, emotional and relational- systemic 
interventions are combined under a constructivist episte-
mological framework.30
Psychotherapy
During hospitalisation and day hospital stays, each patient 
attends three daily group therapies that are selected 
based on diagnosis (AN or BN), comorbidity (addic-
tion, personality disorder), age and treatment phase. 
Dialectical- behavioural therapy is offered to patients with 
a personality disorder, and addiction therapy is offered 
to patients with substance abuse. Phase I of treatment 
is intended for newly enrolled patients and focuses on 
achieving awareness of the problem and encouraging 
motivation for change. Phase II then involves psychother-
apeutic work that focuses on the core issues that appear 
to explain and maintain the problems. During this phase, 
hospitalised patients are often given agreed periods of 
leave to consolidate the changes in their natural environ-
ment. Patients attending day hospitals are encouraged 
to lessen their attendance in an agreed pattern. In both 
levels of hospitalisation, home stays are increased in dura-
tion as the patient’s autonomy improves. Finally, phase 
III focuses on relapse prevention and social rehabilitation 
to help the patient participate again in the community 
through work, study and social relationships.
Additional therapies
All patients engage in two forms of family therapy: 
systemic therapy with their family once every 15 days and 
multifamily group sessions held once a month to reduce 
stress in the family and improve communication among 
its members. All patients also follow a personalised dietary 
programme that is formulated to recover lost weight in 
underweight patients, or to promote healthy weight loss 
in patients who are overweight or obese. Some patients 
may also receive pharmacotherapy for symptoms associ-
ated with EDs or for comorbid disorders.
It is well known, especially in patients with a longer 
duration of problems, that significant deficits can exist 
in the important domains of work and/or education with 
consequent financial challenges. Added to these difficul-
ties, patients’ social relationships are often poor and their 
social networks restricted. Reflecting these challenges, all 
patients follow a psychosocial rehabilitation programme 
in which a team of social educators, social workers and 
educational psychologists work with them on these 
areas. The socioeducational programme also ensures 
that patients of school- age continue with their educa-
tion as normally as possible, either within the hospital or 
adapting the treatment to allow attendance at their usual 
school.
Participants
All patients who start treatment for EDs at ITA between 2 
November 2017 and 2 October 2020, are invited to partic-
ipate in this study.
Inclusion and exclusion criteria
Inclusion criteria
 ► A diagnosis of ED: AN, BN, BED, ARFID, OSFEED or 
ED not specified.
 ► To follow treatment for ED in one of the ITA centres.
Exclusion criteria
 ► Refusal to participate (or)
 ► Inability to give valid consent or to understand the 
questionnaires due to language, visual or cognitive 
barriers.
At admission, all patients are informed about the study 
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is recorded if the patient chooses to sign the informed 
consent form. Participation is voluntary and confidential. 
For those younger than 18 years, consent must also be 
signed by an appropriate relative or legal guardian.
Measures
Primary change measures
Clinical Outcomes in Routine Evaluation system
The Clinical Outcomes in Routine Evaluation (CORE) 
system is a family of instruments designed to measure 
change in psychological distress occurring in the context 
of psychotherapy within a transdiagnostic and pan- 
theoretical framework ( www. coresystemtrust. org. uk). 
Questionnaires have been translated into more than 25 
languages and the measures are widely used internation-
ally to monitoring change in many services, languages 
and countries. From this family of measures, we included 
the following forms according to participant characteris-
tics and the assessment point (see figure 1).
CORE- Outcome Measure (CORE- OM). The main 
questionnaire consists of 34 items divided across 
four subdomains: subjective well- being, problems or 
symptoms, general functioning and risk. It is suitable 
for adults and has shown good psychometric proper-
ties in evaluations of the original English (Cronbach 
α=0.75–0.94) and the Spanish (α=0.71–0.94) versions 
in samples from the UK and Spain.31–33
CORE Short Form (CORE- SFA/CORE- SFB). These 
short versions of CORE consist of 18 items each taken 
from among the 34 items of the CORE- OM and are 
administered alternately to minimise memory effects. 
Due to the item selection, they are comparable and 
offer scores on the same subdomains as the CORE- 
OM,31 32 showing internal consistency (α=0.94).34
Young Person’s CORE (YP- CORE). This question-
naire was originally developed for use in people aged 
11–16 years and comprises 10 items with results given 
on a single global scale. It is widely used for young 
people up to the age of 25 in many services. Both the 
original (α=0.73–0.80)35 36 and the Spanish version 
(α=0.72–0.86)37 have shown good psychometric 
properties.
Secondary outcomes
Eating Attitudes Test and Children’s Eating Attitudes Test
The Eating Attitudes Test (EAT-26) is a self- completed 
26- item scale that is intended to assess the risk of having 
an ED.38 39 Each item has six response options and they 
are scored on three scales: diet, BN and concern with 
food. Although intended as a screening instrument it has 
been widely used as a severity index. For patients under 
16 the Children’s Eating Attitudes Test (ChEAT)40–42 
replaced the EAT-26. This is similar to EAT-26 but written 
with simpler words. Both instruments are widely used and 
have shown good psychometric properties (EAT, English 
α=0.90, Spanish α=0.86; ChEAT, English α=0.76, Spanish 
α=0.86).
Bulimic Investigatory Test of Edinburgh
This 33- item questionnaire was designed for use in BN 
and BED43 and generates scores for two subscales: eating 
symptoms and severity. Both the original (α=0.62–0.96) 
and the Spanish (α=0.63–0.82)44 versions have shown 
good psychometric properties. In our study, we used the 
Figure 1 Schedule for data collection and assessments for a 12- month treatment. This table represents an example of data 
collection and assessment for patients within the service for 1 year. Data collection beyond that point continues as it was in 
the first year until the termination of intensive data collection in October 2020. From November 2020 to end of October 2025, 
CORE- OM and EAT-26 (or ChEAT-26) will be administered every 3 months. BITE, Bulimic Investigatory Test of Edinburgh; 
ChEAT-26, Children’s Eating Attitudes Test; CORE- OM, Clinical Outcomes in Routine Evaluation- Outcome Measure; CORE- SFA, 
Clinical Outcome in Routine Evaluation Short Form A; CORE- SFB, Clinical Outcome in Routine Evaluation Short Form B; EAT-
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Bulimic Investigatory Test of Edinburgh (BITE) for all 
patients regardless of diagnosis with the aim of better 
capturing the presence of binges and other abnormal 
eating behaviours in patients with AN.
Body Mass Index
The Body Mass Index (BMI) is a standardised indicator 
that results from dividing weight in kilograms by height 
in metres and is one of the most widely used indices of 
therapeutic weight change in outcome studies of ED 
and obesity programmes. In this study, patients’ weight 
and height is recorded at baseline and then weight every 
month until the end of treatment. If treatment is still in 
course after 30 October 2020, weight will be recorded 
every 3 months until the end of treatment.
Life Satisfaction Scale
This is a 10- point Likert- type single- item scale that asks 
patients to rate the degree to which they are satisfied with 
life at the present time. Although multicomponent scales 
exist that can measure this construct, simple single- item 
scales like this are used in many population studies.45 This 
format was chosen for its efficiency and its theoretical 
consistency, which has been suggested to be greater than 




Participants completed the questionnaires on paper. 
When a new client arrives at any of the centres the recep-
tionist gives the client (and parents if the client is under 
age) copies of the information sheet, consent form and 
initial measures, these explain that the study is voluntary 
and should be discussed with the assessing clinicians. The 
study is then explained orally by the assessing clinician, 
complementing the information on paper and any ques-
tions answered. Where clients agree to participate, they 
then filled in the questionnaires on paper. The data were 
checked, weight and height measured and diagnosis and 
medication data collected by the primary clinician during 
the first weeks of assessment.
An overview of the schedule is provided in figure 1. Type 
of input (inpatient, day hospital or outpatient: ‘inten-
sity’) and other details of the services patients receive 
throughout their treatment in the ITAMITED system are 
also recorded and entered into the database.
Patients who follow treatment in hospitalisation or day hospital
During the first week, the CORE- OM (or YP- CORE) 
and EAT-26 (or ChEAT-26) questionnaires (depending 
on age) are administered, together with the BITE 
questionnaire. This assessment is repeated during the 
second week to reveal any abrupt change secondary 
to admission. The ChEAT-26 and YP- CORE are then 
administered every 3 weeks for participants under the 
age of 16 and the EAT-26 with either the CORE- SFA 
and CORE- SFB (alternated) on the same three weekly 
schedule for adults. The full CORE- OM (or YP- CORE), 
EAT-26 (or ChEAT-26) and BITE questionnaires are 
administered again every 3 months. When the partici-
pant is discharged from any given level of intervention, 
the CORE- OM (or YP- CORE), EAT-26 (or ChEAT-26) 
and the BITE questionnaires are administered at the last 
session of treatment.
Outpatient treatment
Questionnaires are administered by administrative staff 
just before consultation with the psychotherapist. The 
CORE- OM (or YP- CORE), EAT-26 (or ChEAT-26) and 
BITE questionnaires are administered on the first and 
second visits. Again, the YP- CORE is administered for 
participants younger than 16 years and the CORE- SFA 
and CORE- SFB are alternated for adults. The CORE- OM 
(or YP- CORE), EAT-26 (or ChEAT-26) and BITE ques-
tionnaires are then administered every 3 months, and the 
CORE- OM (or YP- CORE) questionnaire is administered 
again at discharge.
For all participants
After the end of October 2020 all participants still in 
treatment move to a much less intensive data collection. 
In this phase only the CORE- OM (or YP- CORE) and 
EAT-26 (or ChEAT-26) are administered approximately 
every 3 months until the end of October 2025. Weight is 
recorded as determined clinically. Pharmacological treat-
ment, current diagnosis and days of different types of care 
are extracted from the services routine database. Every 
12 months, each participant answers the life satisfaction 
scale and the sociodemographic data are recorded again 
to reflect changes (if any) in variables such as marital 
status or occupation.
Data processing
Technical issues with the services’ routine data systems 
mean that data collection in the intensive phase could 
not be achieved from those systems. In this phase, each 
of the eight participating treatment centres entered data 
into its own Excel spreadsheet and a psychologist oversees 
data entry three times per week. Each centre shared their 
spreadsheets weekly with the primary coordinating centre 
where one clinician checked the data again and removed 
identifying information other than a research ID code. 
The pseudonymised spreadsheets were then shared with 
the research centre in UB where they were analysed for 
coherence and data entry problems using an R script.48 
This analysis produced a weekly feedback report for each 
clinical centre noting any omissions or possible or defi-
nite errors in the data. A possible error might be a surpris-
ingly large change in weight, a definite error might be 
a discharge date in the future or before the admission 
date. In addition to flagging possible and definite errors 
the report alerted each centre to the nearest dates for 
review data to be entered: annual for demographic data; 
monthly for weight, height and service use; three weekly 
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To guarantee confidentiality, the coordinator ensures 
that all personal information is removed from the data-
base before it is sent to a member of the team at the 
University of Barcelona so that only the professionals 
directly responsible for patient care within ITA can map 
from study ID codes to clinical ID codes. Data analysis 
and interpretation will always protect against identifica-
tion. All storage and transfers are secure comply with the 
European data protection law (2016/679).
All personal information collected for this study will 
be stored at the ITA centres for a minimum period of 5 
years after the end of the study to ensure rights of access, 
rectification, cancellation, limitation of treatment and 
opposition of the participants. However, the fully anony-
mised data may be stored indefinitely for future research 
and analysis. Options will be explored for releasing the 
dataset to the scientific community in an open reposi-
tory if we can ensure safe use that is compliant with the 




The ITAMITED programme is highly complex and 
personalised, allowing different patients to take very 
different treatment trajectories, such as transfers between 
intervention types, discharge and re- entry, as well as 
differences in psychotropic medication use. In addition, 
patients have a range of primary ED and comorbidities, 
and they have substantial sociodemographic variety. 
There are generally few male patients but a wide age 
range at first contact. This reflects the realities of clinical 
work with patients who often have long histories of prob-
lems and (not infrequently) life- threatening states. These 
issues present unique challenges for data analysis many of 
which simply cannot arise in analyses of controlled trial 
data. The analyses will be based on three tranches of data 
defined by the entry cohorts and by whether the focus 
is on baseline characteristics (and psychometrics) or on 
treatment trajectories and change patterns. Very diverse 
methods of analysis of such complex data are available 
and there is none of the (relative) clarity of analysis of an 
RCT. It was agreed in the creation of the study that data 
analysis in the first 2 years would be restricted to simple 
analysis of baseline psychometric (allowing for removal 
of measures showing unacceptable psychometrics) and 
to description of the participants and baseline/discharge 
change at 1 year and 2 years. These have so far only been 
shared at conferences and inside ITA. A more extensive 
data analysis plan (DAP) is being registered with the 
CERN Zenodo system and will notarise emergent analyses.
Analysis timing
First data tranche
This will focus on the baseline data for participants 
recruited from November 2017 to October 2020. The 
most important focus will be to establish the base-
line distributions of variables that will be used later to 
measure change (ie, BMI, CORE, EAT-26/ChEAT-26 and 
BITE). We will also report the psychometric properties of 
the self- report measures including acceptability, possible 
floor and/or ceiling effects for items, internal reliability 
(Cronbach alpha and McDonald Omega) of scores and 
discriminant and convergent validity. Finally, we will 
explore any differences between centres and any associa-
tions between demographic and clinical variables, such as 
diagnosis or medication.
Second data tranche
This will contain all data collected by the end of October 
2020 (new patients entering the service during October 
2020 will not be invited into the study as they would only 
have the first two data collection points by the time inten-
sive change measures stop). This second data tranche 
will have from 1 month to 3 years of intensive change 
measurement. When analysing these data, the focus will 
be on diversity of interventions and of change, but specif-
ically the following:
 ► Patterns of change in key variables (ie, BMI, CORE, 
EAT-26/ChEAT-26 and BITE).
 ► Predictors of change/outcome, including any differ-
ences between services.
 ► Changes in sociodemographic and clinical interven-
tion variables (ie, diagnosis, medication or hospitali-
sation status).
Third tranche: continuing re-assessment data
To strike a balance between the financial and logistic 
challenges of intensive change data collection and the 
often chronic nature of EDs from the beginning of 
October 2020 no new patients will be invited into the 
study and from the beginning of November 2020 data 
collection will switch to collect questionnaire data only 
every 3 months with the addition of information about 
weight (and height for younger participants), diagnoses, 
medication, days in different types of care from the new 
ITA electronic data system). This data collection will be 
restarted (assuming continuing informed consent) for 
any participants returning to the service after discharge 
in this second period of up to 5 years, that is to the end of 
October 2025.
Cohort size
 ► The plan (see registration) aimed for a total cohort of 
800 to be recruited by the end of October 2020. This 
was achieved with 942 currently recruited.
Specific analyses
Effectiveness
These all address change on the primary and secondary 
outcome variables (see above) and three approaches are 
used.
 ► Baseline/termination change reporting mean change 
with effect sizes (Cohen’s d2 and dz), both with boot-
strapped 95% CIs. These analyses provide the most 
general comparability with existing effectiveness find-
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 ► Multilevel models (MLM) of rates of change. These 
analyses are increasingly replacing baseline/termina-
tion analyses and analyse trajectories of change based 
on all repeated measures as opposed to just the first 
and last measures.
 ► Survival analysis by time to reaching scores below clin-
ical cutting points. These methods address the inevi-
table ‘right censoring’ of data in naturalistic data sets, 
that is, that later recruited participants will generally 
have shorter durations of repeated assessment and in 
which participants opt out of either treatment or just 
of research participation, at varying points in their 
potential assessment time.
Predictor/subgroup analyses will address gender, age 
(within the age ranges determine by the measures, that is, 
above or below 18 years for the primary outcome CORE 
measures and above and below 16 years for the EAT-26/
CHEAT secondary measure), specific ED diagnosis, pres-
ence of a personality disorder secondary diagnosis.
Additional analyses will provide context to these effec-
tiveness findings. These will be in four groups:
 ► Careful description of the participants including base-
line demographics and medication.
 ► Analyses of the psychometric properties of all 
measures.
 ► Description of the diversity of change trajectories 
(with attention to the predictors/subgroups noted 
earlier).
 ► Description of diverse trajectories of participants 
including any opting out of therapy and returns, 
medication changes and transitions between levels of 
care.
All reporting will respect the above a priori designa-
tion of primary and secondary outcome variables and 
of predictor/subgroup planned contrasts. Emergent 
findings will be clearly designated as such. The publicly 
available, notarised DAP will detail any post hoc analyses 
arising either to describe emergent findings other than 
the a priori ones detailed above or arising through devel-
opment of new statistical methods.
Patient and public involvement
Patients or the public were not involved in the design, 
conduct, reporting or dissemination plans of our research.
DISCUSSION
The main objective of this study is to appraise the effec-
tiveness of a treatment model designed to deal with 
the complexity and heterogeneity of EDs. This model 
includes personalised treatments at different levels of 
care administered by interdisciplinary teams. Moreover, 
it also features a multicomponent programme consisting 
of individual and group psychotherapy, integrated with 
pharmacological and nutritional treatment. By pursuing 
this goal, we seek to contribute to fill the gap in PBE 
research in EDs, especially conducted in private institu-
tions.49 This approach will help us overcome the artificial 
segmentation that occurs when evaluating healthcare 
processes in isolation.
The comprehensive data collection will support not 
only the general effectiveness analyses (see above) but 
allows identification of different trajectories through the 
care levels and the findings should help predict individual 
treatment outcomes and tailor interventions to personal 
client characteristics.
The naturalistic nature of this study will allow the 
inclusion of the different ED diagnoses as well as their 
comorbid pathologies. In effect, the collection of routine 
clinical data will contribute to PBE, offering results that 
are more directly applicable to routine practice than 
that from controlled trials. In this sense, the character-
istics described for our study sample will enable other 
researchers to compare our findings with their own. Also, 
the psychometric properties estimated for the instruments 
employed will provide further information to assess their 
performance and utility in clinical settings.
The devised dissemination strategy is anchored in 
publication of results in optimal peer- reviewed research 
journals. However, being aware of the current practice/
research gap, we also aim to disseminate findings more 
directly to professionals involved in the treatment of EDs. 
Such actions will seek to promote engagement in collabo-
rative PBE networks allowing routine change data to fuel 
the search for effective and efficient interventions.
A major challenge of this study will be to make routine 
data from clinical practice useful for measuring specific 
outcomes. Participants are being invited to complete 
questionnaires frequently, moving beyond the tradi-
tional approach of taking measurements before and after 
treatment. We believe this step is necessary to capture 
further complexities of change and of the varied treat-
ment trajectories that may establish between those time 
points. Moreover, beyond the results we finally achieve, 
this study also wants to contribute to give a greater role to 
patients, listening to their own evaluations of their state 
in a systematic way. With the future reporting of difficul-
ties and facilitators encountered in the conduction of this 
project we hope to spark the interest of more practitioners 
and researchers in monitoring change in their services. 
As an example, during the COVID-19 outbreak in 2020, 
physical distancing regulations led to interventions at day 
hospitals and outpatient services moved online, as were 
all questionnaires. To deal with this situation was a valu-
able opportunity to adapt PBE not only to routine chal-
lenges, but also to emergent ones.
Study limitations
Complexities occur when so many variables are consid-
ered and each participant has a personalised and 
regular review of their clinical treatment plan. This 
means that estimation of population effects (ie, of 
possible generalisability of findings) inevitably has wide 
confidence intervals for smaller cell sizes. Examples 
include the less common diagnoses; considering both 
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and age groups in demographic terms. Likewise, any 
estimation of the influence of social variables (eg, social 
status, education, employment and parenting) is bound 
to have wide intervals. Consequently, disentangling 
for instance the effects of different intervention levels 
from other predictors can only ever be tentative since 
changes in the level of care are likely to be in response 
to clinical state and risk.
Such PBE work requires collaboration between clin-
ical and administrative staff members, and patients, 
for a long time. As in any study, loss of data arises from 
patients opting out, either at baseline or at any point 
in the repeated- measures data collection. In the latter 
case, the removal of earlier data may be required by 
some participants, while others may give their consent 
to keep their previous information but opt out for the 
remaining study duration. Yet others may simply refuse 
participation on one occasion but participate again on 
later ones. Similarly, professional or administrative errors 
may become another source of data loss, while sometimes 
asking patients to complete the self- report measures will 
be deemed inappropriate according to clinical judge-
ment (eg, when a patient is in a state of agitation). Such 
data will not be missed at random, so appropriate efforts 
will need to be made to describe why they were missing 
and the impact they had on our findings. We are scep-
tical about claims that any methods for imputing missing 
values can be unbiased but such methods will be used for 
sensitivity analyses to explore the possible impacts of data 
losses.
Finally, this study measures only a few of the many plau-
sible variables pertinent to change in EDs: quality social 
support, personal histories or motivation to change. 
Taking into account the numerous and systematic assess-
ments, authors have preferred to focus on some outcomes 
considered central to monitor change, and to only 
address predictors arising from demographic and clin-
ical intervention levels. Clearly, other longitudinal studies 
evaluating the concomitant aspects frequently associated 
to EDs are required in the future.
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